[Alzheimer's disease. Molecular pathology, animal models, and current treatment]

Area of Science:

• Neuroscience
• Pharmacology
• Genetics

Context:

• Approved Alzheimer's disease (AD) drugs offer limited efficacy, primarily managing symptoms rather than halting progression.
• The amyloid hypothesis, while influential, has yielded treatments successful in animal models but not in human clinical trials.
• Existing animal models often fail to replicate key AD pathologies like significant neuronal loss, limiting translational success.

Purpose:

• To highlight the limitations of current Alzheimer's disease treatments and prevalent animal models.
• To introduce novel animal models that better recapitulate AD-associated neurodegeneration and behavioral deficits.
• To emphasize the need for improved preclinical models for successful clinical translation of AD therapies.

Summary:

• Alzheimer's disease research is hampered by treatments that only alleviate symptoms and animal models that do not fully represent human pathology.
• While the amyloid hypothesis has guided research, its translation to effective human therapies has been unsuccessful, possibly due to inadequate preclinical models.
• New animal models exhibiting age-dependent axonal degeneration, substantial neuronal loss, and pronounced behavioral deficits offer a more promising avenue for therapeutic development.

Impact:

• Development of more effective Alzheimer's disease therapies through improved preclinical validation.
• Advancement of our understanding of Alzheimer's disease pathogenesis, particularly concerning neuronal loss.
• Potential for successful clinical translation of novel treatment strategies based on more accurate animal models.